Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care - The ProGERD study

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 1, 2012, Pages 154-164

  Malfertheiner, P ^a   Nocon, M ^b   Vieth, M ^c   Stolte, M ^d   Jaspersen, D ^e   Koelz, H R ^f   Labenz, J ^g   Leodolter, A ^h   Lind, T ⁱ   Richter, K ^j   Willich, S N ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c INSTITUTE OF PATHOLOGY   (Germany)

^d Klinikum Kulmbach   (Germany)

^e KLINIKUM FULDA   (Germany)

^f TRIEMLI HOSPITAL   (Switzerland)

^g Ev Jung Stilling Krankenhaus   (Germany)

^h Klinik für Gastroenterologie Hepatologie Stoffwechsel und Infektions Krankheiten   (Germany)

ⁱ ASTRAZENECA R AND D   (Sweden)

^j ASTRAZENECA   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; NON EROSIVE REFLUX DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFLUX ESOPHAGITIS; REMISSION;

ADULT; AGED; ANTACIDS; ANTI-ULCER AGENTS; COHORT STUDIES; DISEASE PROGRESSION; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 83555162565     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04901.x     Document Type: Article

References (35)

1. Dent J, el-Serag HB, Wallander MA, Johansson S,. Epidemiology of gastro-esophageal reflux disease: a systematic review. Gut 2005; 54: 710-7. (Pubitemid 40559260)
2. El-Serag HB,. Time trends of gastresophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol 2007; 5: 17-26. (Pubitemid 46096825)
3. Wong BC, Kinoshita Y,. Systematic review on epidemiology of gastresophageal reflux disease in Asia. Clin Gastroenterol Hepatol 2006; 4: 398-407.
4. Wiklund I,. Review of the quality of life and burden of illness in gastresophageal reflux disease. Dig Dis 2004; 22: 108-14. (Pubitemid 39274305)
5. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-esophageal reflux disease-an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003; 18: 767-76. (Pubitemid 37323641)
6. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS,. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-8. (Pubitemid 30621983)
7. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R,. The Montreal definition and classification of gastresophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20.
8. Tytgat GN, McColl K, Tack J, et al. New algorithm for the treatment of gastro-esophageal reflux disease. Aliment Pharmacol Ther 2008; 27: 249-56.
9. Fass R,. Proton pump inhibitor failure-what are the therapeutic options? Am J Gastroenterol 2009; 104 (Suppl. 2): S33-38.
10. Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L,. Prognostic factors influencing relapse of esophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 473-82. (Pubitemid 27286945)
11. Freston JW, Triadafilopoulos G,. Review article: approaches to the long-term management of adults with GERD-proton pump inhibitor therapy, laparoscopic fundoplication or endoscopic therapy? Aliment Pharmacol Ther 2004; 19 (Suppl. 1): 35-42. (Pubitemid 38253490)
12. Lauritsen K, Deviere J, Bigard MA, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux esophagitis: Metropole study results. Aliment Pharmacol Ther 2003; 17: 333-41. (Pubitemid 36259395)
13. Lundell L, Attwood S, Ell C, et al. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-esophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 2008; 57: 1207-13.
14. Lundell L,. Surgery of gastresophageal reflux disease: a competitive or complementary procedure? Dig Dis 2004; 22: 161-70. (Pubitemid 39274312)
15. Wang K, Sampliner RE,. Updated guidelines 2008 for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103: 788-797. (Pubitemid 351406009)
16. Koop H, Schepp W, Muller-Lissner S, et al. Consensus conference of the DGVS on gastresophageal reflux. Z Gastroenterol 2005; 43: 163-4. (Pubitemid 40332908)
17. Pace F, Bianchi PG,. Gastresophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol 2004; 99: 946-9. (Pubitemid 39090228)
18. Pace F, Bollani S, Molteni P, Bianchi PG,. Natural history of gastro-esophageal reflux disease without esophagitis (NERD)-a reappraisal 10 years on. Dig Liver Dis 2004; 36: 111-5. (Pubitemid 41115503)
19. Fass R,. Distinct phenotypic presentations of gastresophageal reflux disease: a new view of the natural history. Dig Dis 2004; 22: 100-7. (Pubitemid 39274304)
20. Jankowski JA, Provenzale D, Moayyedi P,. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002; 122: 588-90. (Pubitemid 34117010)
21. Malfertheiner P, Lind T, Willich S, et al. Prognostic influence of Barrett's esophagus and Helicobacter pylori infection on healing of erosive gastro-esophageal reflux disease (GERD) and symptom resolution in non-erosive GERD: report from the ProGERD study. Gut 2005; 54: 746-51. (Pubitemid 40732085)
22. Labenz J, Nocon M, Lind T, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol 2006; 101: 2457-62. (Pubitemid 44665238)
23. Lundell L, Dent J, Bennett JR, et al. Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80. (Pubitemid 29333764)
24. Kulig M, Nocon M, Vieth M, et al. Risk factors of gastresophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004; 57: 580-89. (Pubitemid 38891495)
25. Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastresophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005; 40: 275-85. (Pubitemid 40476458)
26. Nocon M, Labenz J, Jaspersen D, et al. Long-term treatment of patients with gastresophageal reflux disease in routine clinical care-results from the ProGERD study. Aliment Pharmacol Ther 2007; 25: 715-22.
27. Hartmann D, Kudis V, Jakobs R, Riemann JF, Schilling D,. Course of erosive gastresophageal reflux disease (ERD)-a prospective examination under therapeutic daily life conditions with a mean follow-up of 6.5 years. Z Gastroenterol 2006; 44: 1039-42. (Pubitemid 44726968)
28. Manabe N, Yoshihara M, Sasaki A, Tanaka S, Haruma K, Chayama K,. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol 2002; 17: 949-54.
29. Sontag SJ, Sonnenberg A, Schnell TG, Leya J, Metz A,. The long-term natural history of gastresophageal reflux disease. J Clin Gastroenterol 2006; 40: 398-404. (Pubitemid 44318158)
30. Kawanishi M,. Will symptomatic gastresophageal reflux disease develop into reflux esophagitis? J Gastroenterol 2006; 41: 440-3. (Pubitemid 43941910)
31. Isolauri J, Luostarinen M, Isolauri E, Reinikainen P, Viljakka M, Keyrilainen O,. Natural course of gastresophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 37-41. (Pubitemid 27027025)
32. Falk GW,. Barrett's esophagus. Gastroenterology 2002; 122: 1569-91. (Pubitemid 34533554)
33. Meining A, Ott R, Becker I, et al. The Munich Barrett follow up study: suspicion of Barrett's esophagus based on either endoscopy or histology only- what is the clinical significance? Gut 2004; 53: 1402-1407. (Pubitemid 39265256)
34. Hanna S, Rastogi A, Weston AP, et al. Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol 2006; 101: 1416-1420. (Pubitemid 43980611)
35. Falkenback D, Lberg S, Johnsson F, Johansson J,. Is the course of gastresophageal reflux disease progressive? A 21-year follow-up. Scan J Gastroenterol 2009; 44: 1277-1287.